Biotechnology - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

55 to 79 of 2346 results

Australian government plans no action on Pharmaceutical Patent Review

Australian government plans no action on Pharmaceutical Patent Review

27-03-2014

The Australian federal government last week released a statement on the Pharmaceutical Patent Review…

Asia-PacificAustraliaBiotechnologyPatentsResearch

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

27-03-2014

Stockholm-based Swedish Orphan Biovitrum has released disappointing top-line results from a Phase III…

BiotechnologyKiobrinaMetabolicsResearchSwedish Orphan Biovitrum

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

Proposed new bill would create new patent term extension for certain biologics patents in USA

Proposed new bill would create new patent term extension for certain biologics patents in USA

26-03-2014

Earlier this week in the USA, legislation was introduced allowing new sponsors to gain intellectual property…

BiotechnologyLegalNorth AmericaPatentsPoliticsUSA

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

Adaptimmune announces appointment of James Noble as Chief Executive Officer

Adaptimmune announces appointment of James Noble as Chief Executive Officer

26-03-2014

Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced…

AdaptimmuneBiotechnologyBoardroomImmunocoreUK

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

26-03-2014

German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal…

AllergopharmaBiotechnologyBoardroomGermanyMerck KGaAPharmaceutical

Angle appointments new Scientific Adviser

Angle appointments new Scientific Adviser

26-03-2014

Angle (AIM:AGL), the specialist medtech company, has appointed Clive Stanway as a Scientific Adviser…

AngleBiotechnologyBoardroomCancer Research TechnologyOncologyUK

EU approval for Cometriq in medullary thyroid carcinoma

EU approval for Cometriq in medullary thyroid carcinoma

25-03-2014

The European Commission has approved Cometriq (cabozantinib), a drug for the treatment of adult patients…

BiotechnologyCometriqEuropeExelixisOncologyRegulationSwedish Orphan Biovitrum

AstraZeneca unit debuts new open innovation platform for partnering programs

25-03-2014

Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support…

AstraZenecaBiotechnologyResearch

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis

25-03-2014

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

Positive CHMP opinion for Janssen’s simeprevir for chronic hepatitis C

24-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen R&D Ireland has received a positive…

Anti-viralsEuropeJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalRegulationsimeprevir

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Report: New drugs needed for prostate cancer as incidents rise

Report: New drugs needed for prostate cancer as incidents rise

21-03-2014

Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand…

EuropeJohnson & JohnsonOncologyPharmaceuticalResearchUSAXtandiZytiga

US FDA eases clinical hold on Geron’s imetelstat

US FDA eases clinical hold on Geron’s imetelstat

21-03-2014

There was a touch of good news yesterday for Geron Corp, after the US Food and Drug Administrated partially…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

20-03-2014

Following an Independent Data Monitoring Committee recommendation based on positive efficacy, a Johnson…

Invega SustennaJanssenJohnson & JohnsonNeurologicalpaliperidone palmitatePharmaceuticalResearch

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

55 to 79 of 2346 results

Back to top